COCésar Alberto Ortiz Orozco

César Alberto Ortiz Orozco

*This is an algorithmically generated author record based on publicly available information.

César Alberto Ortiz Orozco has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional Reversal as a Feasible Option for Malnutrition in Patients With Hyper-Response Following Roux-en-Y Gastric Bypass: A Case Report

    by Martha P Sánchez Muñoz, César A Ortiz Orozco, José D Reyes Blandón, Carlos M Moreno Mendoza, Soledad Aldana Aguiñaga

    Obesity is recognized as a global epidemic, and bariatric surgery is the most effective treatment for obesity and its associated comorbidities, providing durable long-term outcomes. However, a subset of patients develops malnutrition as a complication despite adequate nutritional supplementation, for whom revisional surgery may be indicated, although such procedures can be technically and clinically challenging.


  • Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery

    by Martha Patricia Sánchez Muñoz, José Daniel Reyes Blandón, Ileana Susana Camba Gutierrez, Carlos Manuel Moreno Mendoza, Ma. Soledad Aldana Aguiñaga, César Alberto Ortiz Orozco

    Preoperative management of patients living with severe obesity can be challenging; in this context, the preoperative weight loss may help to obtain better outcomes and less morbidity for bariatric surgery. Therefore, we evaluated the effectiveness of GLP-1 analogue Liraglutide in preoperative weight loss. We performed a single-center, quasi-experimental prospective study. Eligible participants were adults in preoperative management for bariatric-metabolic surgery with body-mass index ≥ 48 kg/m2. All patients were assigned liraglutide treatment, with an initial dose of 0.6 mg subcutaneous per day, the dose was increased each week until reaching 3.0 mg for 12 weeks. Weight loss and body composition were evaluated monthly using bioelectric impedance (BIA) (InBody 770 Scale®). We analyzed data using descriptive statistics, central tendency measures and dispersion for quantitative variables and absolute and relative frequencies for qualitative variables. A total of 37 individuals were included in this study, 28 (76%) were female and 9 (24%) were males, with an average age of 44 years. About the BMI, 19 patients (51%) had a BMI > 50 kg/m2, 10 (27%) > 40 kg/m2 and 8 (22%) > 60 kg/m2; with a total average BMI of 56.04 kg/m2. The initial weight was 147.4 ± 14.9 kg which decreased to 139.3 ± 16.8 kg; after 3 months of liraglutide administration. A total of 35 patients had some degree of weight loss (94.6%), while 2 (5.40%) had no weight changes. The total weight loss was 5.50% at 3 months of liraglutide treatment. Liraglutide could be an effective adjuvant therapy for preoperative weight loss in patients living with severe obesity.


  • Transferrin Saturation, Serum Ferritin, and C-Reactive Protein vs. Serum Ferritin for an optimal Iron Deficiency Diagnosis in Candidates for Bariatric Surgery

    by M. Patricia Sánchez Muñoz, Zuleyma P. Bello Ramirez, Eduardo L. Martínez Rodriguez, José D. Reyes Blandón, Soledad Aldana Aguiñaga, César A. Ortiz Orozco, Allison R. Esparza Yáñez

    Introduction Iron has different physiological processes and is regulated by hepcidin that is also an acute phase reactant, which increases with inflammation. Obesity produces a pro-inflammatory state, affecting directly the normal regulation of iron, causing ferritin (FER) deficiency. FER is used as the only indicator of the status of iron in patients with obesity, so the majority of them would be underdiagnosed, leading to a high prevalence of iron deficiency (ID) and anemia. The aim of this study is to evaluate the diagnostic tests: transferrin saturation (TS), FER, and C-reactive protein (CRP) vs. FER with the objective of analyzing the most accurate variable for the diagnosis of ID. Materials and Methods We present a cross-sectional, analytical, and retrospective study, evaluating the diagnostic tests in 96 patients, to whom two methods were applied for the diagnosis of ID: method 1 (FER < 30 ng/mL) and method 2 divided into 2A (FER < 30 ng/mL), 2B (FER 30–100 ng/mL + CRP ≥ 5 mg/L), 2C (FER 100–300 ng/mL + CRP ≥ 5 mg/L + TS < 20%), and 2D (TS < 20%). Results The prevalence of ID obtained using method 1 was 30.2% while 69.8% presented ID using total method 2, confirming an underdiagnosis of 39.6%. Conclusion The inflammatory state in patients with obesity must be considered in the diagnosis of ID. The use of TS, FER, and CRP has greater validity than the use of serum FER for the diagnosis of ID in patients with obesity. Graphical Abstract